Lymphoma Clinical Trials in Los Angeles

Showing 241-260 of 445 trials

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

NCT03775525

This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients with Advanced Solid Tumors or Lymphoma

Advanced CancerGastric CancerBreast Cancer+14 more

Genzada Pharmaceuticals USA, Inc.127 participantsStarted Mar 2019

Scottsdale, Arizona, United States • Los Angeles, California, United States • New Orleans, Louisiana, United States +1 more locations

COMPLETEDPhase 1/2< 1 mile

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

NCT03770000

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.

T Cell Lymphoma

Rhizen Pharmaceuticals SA33 participantsStarted Mar 2019

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +12 more locations

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Lymphoma Trials in Other Cities

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

A Study of LY3023414 in Participants With Advanced Cancer

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)

Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)

Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Other Conditions in Los Angeles